Neuromyelitis Optica (Devic’s Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Neuromyelitis Optica (Devic’s Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica (Devic’s Syndrome) - Drugs In Development, 2022, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline landscape.

Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person’s immune system (the body’s natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica (Devic’s Syndrome) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 4, 8, 1, 1, 14, 3 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Neuromyelitis Optica (Devic’s Syndrome) – Overview
Neuromyelitis Optica (Devic’s Syndrome) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neuromyelitis Optica (Devic’s Syndrome) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuromyelitis Optica (Devic’s Syndrome) – Companies Involved in Therapeutics Development
Accendatech Co Ltd
Aeterna Zentaris Inc
Ahead Therapeutics SL
Alexion Pharmaceuticals Inc
Apsara Therapeutics
Beijing Mabworks Biotech Co Ltd
Bio-Thera Solutions Ltd
Biogen Inc
Boston Pharmaceuticals Inc
Chord Therapeutics Sarl
Chugai Pharmaceutical Co Ltd
Cour Pharmaceuticals Development Co Inc
Elixiron Immunotherapeutics Inc
Endece LLC
EnhanX Biopharm Inc
Eternity Bioscience Inc
Guangzhou Lupeng Pharmaceutical Co Ltd
H. Lundbeck AS
HanAll Biopharma Co Ltd
Horizon Therapeutics Plc
ImCyse SA
ImmunAbs Inc
Imstem Biotechnology Inc
InnoCare Pharma Ltd
LFB SA
Mitsubishi Tanabe Pharma Corp
Nanjing Iaso Biotherapeutics Co Ltd
NovelMed Therapeutics Inc
Oculis SA
Orion BioScience Inc
PlateletBio
RemeGen Co Ltd
Samsung Bioepis Co Ltd
Shanghai Pharmaceutical Group Co Ltd
SinoMab Bioscience Ltd
Tasly Biopharmaceuticals Co Ltd
Neuromyelitis Optica (Devic’s Syndrome) – Drug Profiles
ACT-001 – Drug Profile
AIM Biologicals – Drug Profile
AT-1511 – Drug Profile
B-001 – Drug Profile
B-2067 – Drug Profile
B-20672 – Drug Profile
BAT-4406F – Drug Profile
batoclimab – Drug Profile
BOS-172767 – Drug Profile
Cellular Immunotherapy for Central Nervous System Disorders – Drug Profile
cladribine – Drug Profile
CT-103A – Drug Profile
D-15107 – Drug Profile
eculizumab – Drug Profile
eculizumab biosimilar – Drug Profile
EI-1071 – Drug Profile
ENX-201 – Drug Profile
Gene-Modified Cell Therapy for Neuromyelitis Optica – Drug Profile
IM-101 – Drug Profile
IMS-001 – Drug Profile
IMS-002 – Drug Profile
inebilizumab – Drug Profile
LP-168 – Drug Profile
Lu-AG22515 – Drug Profile
MIL-62 – Drug Profile
Monoclonal Antibody to Inhibit C3 and C5 for Neuromyelitis Optica – Drug Profile
NDC-1308 – Drug Profile
OCS-05 – Drug Profile
orelabrutinib – Drug Profile
ORNx-KI – Drug Profile
ravulizumab LA – Drug Profile
Recombinant Enzyme to Inhibit IgG for Neuromyelitis Optica – Drug Profile
Recombinant Peptide for Neuromyelitis Optica – Drug Profile
rituximab – Drug Profile
satralizumab – Drug Profile
SHR-1459 – Drug Profile
SM-06 – Drug Profile
Synthetic Peptide for Neuromyelitis Optica – Drug Profile
telitacicept – Drug Profile
ublituximab – Drug Profile
unasnemab – Drug Profile
Neuromyelitis Optica (Devic’s Syndrome) – Dormant Projects
Neuromyelitis Optica (Devic’s Syndrome) – Discontinued Products
Neuromyelitis Optica (Devic’s Syndrome) – Product Development Milestones
Featured News & Press Releases
May 05, 2022: Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder
May 03, 2022: EC approves Horizon's Uplizna for neuromyelitis optica spectrum disorder
May 02, 2022: Horizon Therapeutics receives European Commission (EC) approval of UPLIZNA (inebilizumab) for the treatment of adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Apr 11, 2022: Aeterna Zentaris abstract accepted for presentation at 13th International Congress on Autoimmunity
Mar 31, 2022: New analysis finds UPLIZNA (inebilizumab-cdon) effective for people with newly-presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)
Mar 14, 2022: Hansoh Pharmaceutical Group Company drug registration approval of Inebilizumab injections
Mar 01, 2022: InnoCare announces approval of Phase II clinical trial using Orelabrutinib for the treatment of NMOSD in China
Feb 16, 2022: New analysis demonstrates UPLIZNA (inebilizumab-cdon) reduces severity of attacks associated with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Dec 14, 2021: RemeGen reiterates commitment to its battle against autoimmune disease on World Strengthened Immunity Day 2021
Nov 22, 2021: New analysis published in Multiple Sclerosis and Related Disorders supports the efficacy of UPLIZNA (inebilizumab-cdon) in patients previously treated with rituximab for neuromyelitis optica spectrum disorder (NMOSD)
Nov 17, 2021: Shanghai Pharmaceuticals recombinant anti-CD20 humanized monoclonal antibody injection obtained clinical trial approval notice
Nov 12, 2021: Horizon Therapeutics plc receives CHMP positive opinion for UPLIZNA (inebilizumab) as a monotherapy for the treatment of adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Oct 14, 2021: Roche’s Enspryng lowers disease relapses in Phase III NMOSD trials
Oct 13, 2021: April Bio, U.S. FDA approval of IND for Phase 1 clinical trial for Autoimmune disease treatment
Oct 13, 2021: New data reinforce the relationship between B-cell depletion and improved outcomes in people receiving UPLIZNA (inebilizumab-cdon) for neuromyelitis optica spectrum disorder (NMOSD)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Universities/Institutes, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Products under Development by Companies, 2022 (Contd..2)
Table 8: Products under Development by Universities/Institutes, 2022
Table 9: Number of Products by Stage and Target, 2022
Table 10: Number of Products by Stage and Mechanism of Action, 2022
Table 11: Number of Products by Stage and Route of Administration, 2022
Table 12: Number of Products by Stage and Molecule Type, 2022
Table 13: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Accendatech Co Ltd, 2022
Table 14: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Aeterna Zentaris Inc, 2022
Table 15: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Ahead Therapeutics SL, 2022
Table 16: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Alexion Pharmaceuticals Inc, 2022
Table 17: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Apsara Therapeutics, 2022
Table 18: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Beijing Mabworks Biotech Co Ltd, 2022
Table 19: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Bio-Thera Solutions Ltd, 2022
Table 20: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Biogen Inc, 2022
Table 21: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Boston Pharmaceuticals Inc, 2022
Table 22: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Chord Therapeutics Sarl, 2022
Table 23: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Table 24: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Cour Pharmaceuticals Development Co Inc, 2022
Table 25: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Elixiron Immunotherapeutics Inc, 2022
Table 26: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Endece LLC, 2022
Table 27: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by EnhanX Biopharm Inc, 2022
Table 28: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Eternity Bioscience Inc, 2022
Table 29: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Guangzhou Lupeng Pharmaceutical Co Ltd, 2022
Table 30: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by H. Lundbeck AS, 2022
Table 31: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by HanAll Biopharma Co Ltd, 2022
Table 32: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Horizon Therapeutics Plc, 2022
Table 33: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by ImCyse SA, 2022
Table 34: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by ImmunAbs Inc, 2022
Table 35: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Imstem Biotechnology Inc, 2022
Table 36: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by InnoCare Pharma Ltd, 2022
Table 37: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by LFB SA, 2022
Table 38: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Table 39: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Nanjing Iaso Biotherapeutics Co Ltd, 2022
Table 40: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by NovelMed Therapeutics Inc, 2022
Table 41: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Oculis SA, 2022
Table 42: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Orion BioScience Inc, 2022
Table 43: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by PlateletBio, 2022
Table 44: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by RemeGen Co Ltd, 2022
Table 45: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Samsung Bioepis Co Ltd, 2022
Table 46: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
Table 47: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by SinoMab Bioscience Ltd, 2022
Table 48: Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Tasly Biopharmaceuticals Co Ltd, 2022
Table 49: Neuromyelitis Optica (Devic’s Syndrome) – Dormant Projects, 2022
Table 50: Neuromyelitis Optica (Devic’s Syndrome) – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Routes of Administration, 2022
Figure 9: Number of Products by Stage and Routes of Administration, 2022
Figure 10: Number of Products by Molecule Types, 2022
Figure 11: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings